Akèy › Limfom Difize Gwo Selil B › Ohio
Etid klinik pou Limfom Difize Gwo Selil B nan Ohio
24 etid pou Limfom Difize Gwo Selil B ap chèche patisipan nan sit nan Ohio.
Vil nan Ohio
Tèks ofisyèl etid la (Anglè)
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Aultman Health Foundation, Canton
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- Ohio State University Comprehensive Cancer Center, Columbus
- ak 1 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06649812A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- University Hospitals Cleveland Medical Center, Cleveland
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06091865A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- University of Cincinnati Medical Center ( Site 0156), Cincinnati
- University Hospitals of Cleveland ( Site 0155), Cleveland
- Fairview Hospital-Moll Cancer Center ( Site 0198), Cleveland
- ak 2 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06890884A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Oncology_Hematology Care Clinical Trials, LLC (OHC) ( Site 8002), Cincinnati
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06717347A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Cleveland Clinic, Cleveland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- The Ohio State University (OSU), Columbus
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07226843Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, Cleveland
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07225439Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Oncology Hematology Care - Kenwood, Cincinnati
- University of Cincinnati Medical Center, Cincinnati
- Cleveland Clinic, Cleveland
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 31, 2026 · NCT06500273Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
- Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT06536049Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- University of Cincinnati (UC) Physicians Company, LLC, Cincinnati
- Cleveland Clinic, Cleveland
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT05826535Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- The Ohio State University Wexner Medical Center, Columbus
Ap rekriteFaz 1/2
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Oncology Hematology Care Clinical Trials, Cincinnati
- University of Cincinnati, Cincinnati
- Cleveland Clinical Taussig Cancer Center, Cleveland
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT07188558A Long-term Extension Study of PCI-32765 (Ibrutinib)
- The Ohio State University- James Cancer Hospital, Columbus
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT01804686DALY II USA/ MB-CART2019.1 for DLBCL
- The Ohio State University Wexner Medical Center James Cancer, Columbus
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
- The Ohio state University, Columbus
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 10, 2026 · NCT05077527Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Case Western Reserve University, Cleveland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 9, 2026 · NCT06015880A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Cincinnati Medical Center, Cincinnati
- Cleveland Clinic, Cleveland
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 2, 2026 · NCT05131022Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Cincinnati Children's Hospital Medical Center, Cincinnati
Ap rekriteEtid obsèvasyon
Laj 0 a 38 · Tout sèks · Mizajou Jun 4, 2026 · NCT06131801The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Gabrail Cancer Center Research,, Canton
Ap rekriteFaz 1/2
Laj 12 a 95 · Tout sèks · Mizajou Apr 15, 2026 · NCT04329728Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- University of Cincinnati, Cincinnati
- Ohio State University, Columbus
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT04775745Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Case Western Reserve University, Cleveland
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Feb 2, 2026 · NCT05633615A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- University Hospitals Cleveland Medical Center, Cleveland
- The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2025 · NCT05780034DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Toledo Clinic Cancer Center, Toledo
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Apr 7, 2023 · NCT04920617Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
- University of Cincinnati, Cincinnati
- The Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2022 · NCT04502394Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.